UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 13, 2011
Echo Therapeutics, Inc.
(Exact name of Company as specified in its charter)
|
Delaware
|
000-23017
|
41-1649949
|
||
|
(State or other jurisdiction
of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
|
8 Penn Center
1628 JFK Blvd., Suite 300
Philadelphia, PA
|
19103
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Company’s telephone number, including area code: (215) 717-4100
__________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.07. Submission of Matters to a Vote of Security Holders.
At our 2011 Annual Meeting of Shareholders (the “Annual Meeting”) held on July 13, 2011, the following matters were acted upon by our shareholders:
|
1.
|
The election of two Class 1 directors and two Class 3 directors to the Company’s Board of Directors; and
|
|
2.
|
The ratification of the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2011.
|
As of May 16, 2011, there were 34,017,174 shares of common stock issued and outstanding. The results of voting on each of the matters presented to shareholders at the Annual Meeting are set forth below:
|
VOTES
FOR
|
VOTES AGAINST / WITHHELD
|
ABSTENTIONS
|
BROKER
NON-VOTES
|
|||||||||||||
|
Election of directors:
|
||||||||||||||||
|
William F. Grieco (Class 1)
|
14,790,914 | 159,920 | — | 10,772,003 | ||||||||||||
|
James F. Smith (Class 1)
|
14,937,914 | 12,920 | — | 10,772,003 | ||||||||||||
|
Patrick T. Mooney, M.D. (Class 3)
|
14,937,504 | 13,330 | — | 10,772,003 | ||||||||||||
|
Shawn K. Singh, J.D. (Class 3)
|
14,790,904 | 159,930 | — | 10,772,003 | ||||||||||||
|
Ratification of Wolf & Company
|
25,608,395 | 20,075 | 94,367 | — | ||||||||||||
Vincent D. Enright continues his term of office as a Class 2 director following the Annual Meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ECHO THERAPEUTICS, INC.
Dated: July 18, 2011
|
|
By: /s/ Patrick T. Mooney
Patrick T. Mooney
Chief Executive Officer and President
|